Medicare AdvantageCoverageMedium impact
MA08.180, Axatilimab-csfr (Niktimvo™) for Intravenous Use
Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.180 has been created for Axatilimab-csfr (Niktimvo™), a new intravenous medication. This establishes coverage criteria and billing guidelines for this recently approved drug therapy.
Action Required
By July 28, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Axatilimab-csfr (Niktimvo™). Update drug formulary lists and billing protocols once complete policy details are available.